BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 35197523)

  • 1. Prognostic signature based on m6A-related lncRNAs to predict overall survival in pancreatic ductal adenocarcinoma.
    Wu Q; Chen L; Miao D; Jin Y; Zhu Z
    Sci Rep; 2022 Feb; 12(1):3079. PubMed ID: 35197523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
    Hu Y; Chen Y
    Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma.
    Li XQ; Yin SQ; Chen L; Tulamaiti A; Xiao SY; Zhang XL; Shi L; Miao XC; Yang Y; Xing X
    BMC Cancer; 2024 Jan; 24(1):116. PubMed ID: 38262966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer.
    Liu Y; Wang T; Fang Z; Kong J; Liu J
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma.
    Qiu Y; Wang X; Fan Z; Zhan S; Jiang X; Huang J
    Immun Inflamm Dis; 2021 Dec; 9(4):1596-1612. PubMed ID: 34432955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
    Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
    Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel genomic instability-derived lncRNA signature to predict prognosis and immune characteristics of pancreatic ductal adenocarcinoma.
    Yang H; Zhang W; Ding J; Hu J; Sun Y; Peng W; Chu Y; Xie L; Mei Z; Shao Z; Xiao Y
    Front Immunol; 2022; 13():970588. PubMed ID: 36148233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer.
    Zhao Z; Yang YB; Li XY; Li XG; Chu XD; Lin ZB; Zhang YR; Guo YG; Ding H; Pan YL; Wang L; Pan JH
    Dis Markers; 2021; 2021():8686307. PubMed ID: 34745388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and validation of a novel immunological model to predict prognosis in pancreatic ductal adenocarcinoma.
    Liu J; He M
    Int Immunopharmacol; 2024 Jun; 134():112266. PubMed ID: 38761784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma.
    Song J; Xu Q; Zhang H; Yin X; Zhu C; Zhao K; Zhu J
    J Cell Biochem; 2018 Jun; 119(6):4559-4569. PubMed ID: 29239017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
    Zhao J; Lin X; Zhuang J; He F
    Front Genet; 2021; 12():714697. PubMed ID: 34777460
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of a novel m6A-related lncRNA pair signature for predicting the prognosis of gastric cancer patients.
    Wang JM; Li X; Yang P; Geng WB; Wang XY
    BMC Gastroenterol; 2022 Feb; 22(1):76. PubMed ID: 35189810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma.
    Yuan H; Liu J; Zhao L; Wu P; Chen G; Chen Q; Shen P; Yang T; Fan S; Xiao B; Jiang K
    Front Immunol; 2021; 12():800268. PubMed ID: 34956238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
    Song Y; Qu H
    BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients.
    Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C
    BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-Talk Between m
    Song W; Ren J; Xiang R; Yuan W; Fu T
    Front Immunol; 2022; 13():740960. PubMed ID: 35350786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
    Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.